TrialEuropean journal of immunology2016

Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.

Susanne M Cabrera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.